QURE - MCAP CO - uniQure N.V.

The market price visualization for uniQure N.V. (QURE) is presented below; the company has optimized drug production by delegating final testing to external contractors to minimize risks. This biotech leader is implementing advanced treatments for orphan diseases while actively investing in scientific research. The business economics rely on partnership royalties, medical trial results, and the efficiency of its own plants, with a market capitalization of 2.64.

The current market valuation of uniQure N.V. (QURE) reflects market optimism regarding royalties from hemophilia B therapy and the potential of new developments targeting Alzheimer's and Huntington's diseases. This indicator is calculated as the product of the total number of shares and their current price, capturing the objective scale of the business and signaling correction risks in the event of overvalued quotes or negative financial reporting.